Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600338 | 0.96 | MAPT (0.47) | MAPTKDM4ETP53NPY5RSMN1; SMN2 | |
| SCHEMBL2600340 | 0.89 | SMN1; SMN2 (0.53) | MAPTKDM4ETP53NPY5RSMN1; SMN2 | |
| SCHEMBL2600341 | 0.89 | MAPT (0.47) | MAPTKDM4ETP53NPY5RSMN1; SMN2 | |
| SCHEMBL2600329 | 0.88 | NPY5R (0.44) | MAPTTP53NPY5RSMN1; SMN2MEN1 | |
| SCHEMBL2600332 | 0.81 | SMN1; SMN2 (0.54) | MAPTKDM4ETP53NPY5RSMN1; SMN2 | |
| SCHEMBL2600335 | 0.80 | NPY5R (0.55) | MAPTTP53NPY5RSMN1; SMN2MEN1 | |
| SCHEMBL2600342 | 0.80 | SMN1; SMN2 (0.51) | MAPTKDM4ETP53NPY5RSMN1; SMN2 | |
| SCHEMBL2600330 | 0.79 | NPY5R (0.45) | MAPTTP53NPY5RSMN1; SMN2MEN1 | |
| SCHEMBL2600333 | 0.79 | NPY5R (0.54) | NPY5R | |
| SCHEMBL2600344 | 0.79 | NPY5R (0.43) | MAPTTP53NPY5RSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372833-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8372833-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-20120095231-A1 | UREA DERIVATIVE | YANO TOSHISADA (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095231-A1 | UREA DERIVATIVE | YANO TOSHISADA (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8088777-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088777-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090203712-A1 | Urea Derivative | SHIONOGI &CO., LTD. | 2009-08-13 | — | — | US | disclosed |
| US-20090203712-A1 | Urea Derivative | SHIONOGI &CO., LTD. | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095231-A1 | UREA DERIVATIVE | NPY5R, NPY1R, NPY2R | MAPT 2307/4885KDM4E 2072/4885TP53 3688/4885 |
| US-20090203712-A1 | Urea Derivative | NPY5R, NPY1R, NPY2R | MAPT 2336/4885KDM4E 2024/4885TP53 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.